The administration of GPVI-Fc-PEG (0.18 mg per day) showed an increase in reperfusion and an improvement in the survival following cerebral thrombosis in a murine model, compared with treatment with GPVI alone and without the risk of intracranial bleeding [118]. This evidence concerns the gene GP6 and intracranial thrombosis.